Mumbai: GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma) has received a tax demand of Rs 23.21 crore from the Income Tax Department following a scrutiny assessment for the Assessment Year 2023-24.The order, dated March 23, 2026, was issued by the Centralized Processing Centre (CPC) and was received by the company on March 24, 2026.According to the company’s regulatory disclosure, the demand arises post completion of the assessment proceedings. However, GSK Pharma has stated that it does not agree with the findings and is currently in the process of filing an appeal before the appropriate appellate authority.Also Read: GSK Gets USFDA Nod for Liver Disease-Related Itching Drug LynavoyThe company clarified that, as of now, there is no impact on its financial statements or operations due to this development.The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.Also Read: GSK to Acquire RAPT Therapeutics for USD 2.2 Billion, Bolsters Food Allergy Drug Pipeline